
zzso is a potent inhibitor of the zzso regulators, zzso A and B, and has shown zzso activity in patients with solid and zzso zzso This phase I study assessed safety, zzso zzso and zzso properties of zzso 

Patients with advanced, incurable solid tumors or zzso zzso received zzso as a continuous 24-hour infusion on days 1, 8 of a zzso zzso A 3 + 3 dose escalation design was used with a starting dose of zzso zzso zzso samples were collected from all patients on cycle one, and zzso samples were collected from 4 patients at the recommended phase II dose zzso 

35 patients were zzso for toxicity and 32 were zzso for zzso zzso was well zzso with main zzso being zzso zzso fatigue, gastrointestinal zzso zzso zzso and zzso The dose limiting zzso were zzso zzso zzso zzso and zzso with grade 3 infection (1 zzso at 47 zzso zzso as the maximum tolerated zzso The zzso was 40 zzso zzso analyses showed zzso appeared to follow linear zzso with a mean elimination zzso of zzso zzso zzso analyses showed no consistent or significant changes, but trends suggested evidence of zzso zzso and zzso zzso One patient had partial response and four patients experienced zzso stable disease zzso zzso zzso 

In this study, zzso was well zzso The zzso is 40 zzso on days 1, 8 of a zzso zzso zzso zzso trials will assess efficacy and safety in solid and zzso zzso 

